



Granules India Limited

11nd Floor, 3rd Block, My Home Hub, Madhapur, Hyderabad-500 081. INDIA
Ph : +91-40-66760000, Fax : +91-40-23115145
E-mail : mail@granulesindia.com URL : www.granulesindia.com

Dated April 26th, 2012

The Manager
Listing Department
National Stock Exchange of India Limited
'Exchange Plaza', C-1, Block G,
Bandra-Kurla Complex, Bandra (E),
Mumbai – 400 051

Fax: 022 – 26598237/38

Dear Sir,

Sub: Press Release

Symbol: GRANULES

Enclosed please find a Press Release titled "Granules India Announces Chief Financial Officer".

Kindly take the above information on record

Thanking you,

Yours faithfully,

FOR, GRANULES INDIA LIMITED


(SHIVANGI SHARMA)
Company Secretary &
Compliance Officer



Encl: as above



Press Release

Granules India Announces New Chief Financial Officer

Hyderabad, April 26, 2012: Granules India Ltd., a fast growing pharmaceutical manufacturing company, announced the appointment of Mr. VVS Murthy as Chief Financial Officer. Mr. Pranesh Raj Mathur, who had the dual role of President – Active Pharmaceutical Ingredient (API) Division and CFO will continue his role as the President of the API Division.

Mr. Murthy previously served as Group Chief Financial Officer at Dishman Pharmaceuticals and Chemicals Ltd. and has over 32 years of experience in the Finance industry including 17 years in the Pharmaceutical Industry.

“The addition of Mr. Murthy to the senior management team will ensure that we are able to move quickly and capitalize on new opportunities. Mr. Murthy’s knowledge in optimizing financial systems, working with foreign subsidiaries and M&A experience will be beneficial as our Company continues to grow. Mr. Mathur, who has served as CFO for 8 years, has been instrumental in our sustainable growth including guiding the Company through capital raises and being a key member in the formation of Granules-Biocause, our Chinese Joint-Venture. Mr. Mathur, who recently completed his EMBA at the Indian School of Business, will focus his energy on taking P&L responsibilities for our API Division” said C. Krishna Prasad, Managing Director of Granules.

About Granules India Ltd.

(BSE: 532482, NSE: GRANULES)

Granules is a fast growing pharmaceutical manufacturing company with world class facilities and is committed to manufacturing excellence, quality and customer service. The Company produces Finished Dosages (FDs), Pharmaceutical Formulation Intermediates (PFIs) and Active Pharmaceutical Ingredients (APIs) for quality conscious customers in the regulated and semi-regulated markets. Granules support customers with unique value, extensive product range, proactive solutions and a global network of associates. The Company’s global presence extends to over 300 customers in 50 countries through offices in India, U.S., U.K., China and Colombia. Granules offer all three components of the pharmaceutical value chain which gives the customers flexibility and choice.

Granules has the largest PFI facility in the world with an industry leading 6 ton batch size. The Company has its own ANDAs and dossiers which enable customers to quickly enter a market instead of filing their own applications. Granules has a highly skilled regulatory affairs department that can offer customers support and can help them navigate through regulatory issues.

Granules has strengthened its advantages through its Operational Excellence (OE) department which looks at every step of the manufacturing process in order to gain efficiencies and has also implemented systems that have standardized quality and reduced variation. The Company’s OE program is regularly cited by MNCs as a “best in class” program and is the comparative advantage that lets Granules provide world-class quality products at a lower cost than its competitors. The adoption of the OE philosophy by Granules has earned it several recognitions including The Economic Times Manufacturing Excellence Awards 2011.

Caution Statement:

Certain statements made above may be “forward looking statements” within the meaning of applicable laws and regulations.

Contacts:

Rukmini Baxi/ Divya Balasubramaniam

Genesis Burson-Marsteller

+91 964 232 0044/ +91 9962560024

rukmini.baxi@bm.com/divya.bala@bm.com